Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

RVXoldtimer

Rank: President [?]

Points: 3190 [?]

Votes: 23 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Promissory Note

posted on Jan 30, 2021 05:19PM

Since the last Exempt Distribution, on January 27th, ZCC reports a Promissory Note for $447,125.00 CAD. With this they also issued 100,000 common share purchase warrants exercisable at $1.92 until January 27th, 2026.

2 Recommendations